Lack of association between clopidogrel responsiveness tested using point-of-care assay and prognosis of patients with coronary artery disease

  • Petra Paulu
  • Pavel Osmancik
  • Petr Tousek
  • Marek Minarik
  • Lucie Benesova
  • Zuzana Motovska
  • Frantisek Bednar
  • Viktor Kocka
  • Petr Widimsky
Article

Abstract

Dual antiplatelet therapy is important treatment modality across the spectrum of coronary artery disease manifestations. However, a significant number of patients do not have a completely effective response to clopidogrel. This study assessed the impact of response after clopidogrel with Verify Now device on prognosis on patients undergoing coronary interventions. Consecutive patients following percutaneous coronary intervention were prospectively enrolled. A loading dose of 600 mg of clopidogrel was administered before or during PCI. Blood samples were drawn within 24 h after clopidogrel administration. The effect of clopidogrel was measured using VerifyNow. All patients were evaluated at 6 months. The primary end-point was the combination of death, MI and stroke. 378 patients (69.3 % men and 30.7 % women) were enrolled. The mean age was 67.2 ± 12.8 years, BMI 28.9 ± 17.7, and 116 patients had diabetes (30.7 %). During the 6-months follow-up 30 patients (7.94 %) experienced a monitored end-point: 12 patients (3.17 %) had MI; five patients (1.32 %) strokes and 15 patients (3.97 %) died. The remaining 248 patients (71.26 %) were end-point free. Factors associated with a poor prognosis were: leukocytes (OR 1.7 [1.2–2.4], p < 0.01), creatinine (OR 1.4 [1.1–2.5], p < 0.05) and at a borderline level the presence of AA allele of gene CYP2C19*2 (OR 2.5 [0.99–4.1], p = 0.052). The results using VerifyNow were similar between both groups (Group End-point: 208.5 ± 85.5, group No end-point 203.1 ± 91.3) and failed to show any prognostic value (OR 1.00 [0.992–1.007], p = 0.9). The measurement of clopidogrel efficacy using VerifyNow had no prognostic value for our unselected cohort of patients after PCI.

Keywords

Dual antiplatelet therapy Clopidogrel efficacy VerifyNow Prognosis 

Notes

Acknowledgments

Research Grant of Internal Grant Agency of the Ministry of Health of the Czech Republic, No. NS 9988-4/2008.

References

  1. 1.
    Baigent C, Collins R, Appleby P, Parish S, Sleight P, Peto R (1998) ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. BMJ 316(7141):1337–1343PubMedCrossRefGoogle Scholar
  2. 2.
    Antiplatelet Trialists’ Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. BMJ 324:71–86CrossRefGoogle Scholar
  3. 3.
    CAPRIE Steering Committee (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348:1329–1339CrossRefGoogle Scholar
  4. 4.
    Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST segment elevation. N Engl J Med 345:494–502PubMedCrossRefGoogle Scholar
  5. 5.
    Mehta SR, Yusuf S, Peters RJG, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht H, Zhao F, Chrolavicius S, Copland I, Fox KA (2001) Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE Study. Lancet 358:527–533PubMedCrossRefGoogle Scholar
  6. 6.
    Wang TH, Bhatt DL, Topol E (2006) Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J 27:647–654PubMedCrossRefGoogle Scholar
  7. 7.
    Michelson AD (2004) Platelet function testing in cardiovascular diseases. Circulation 110:e489–e493PubMedCrossRefGoogle Scholar
  8. 8.
    Gachet Ch, Aleil B (2008) Testing antiplatelet therapy. Eur Heart J Suppl 10:A28–A134CrossRefGoogle Scholar
  9. 9.
    Ang L, Mahmud E (2008) Monitoring oral antiplatelet therapy: is it justified? Ther Adv Cardiovasc Dis 2:485–496PubMedCrossRefGoogle Scholar
  10. 10.
    Marcucci R, Gori AM, Paniccia R, Giusti B, Valente S, Giglioli C, Buonamici P, Antoniucci D, Abbate R, Gensini GF (2009) Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow up. Circulation 119:237–242PubMedCrossRefGoogle Scholar
  11. 11.
    Price MJ, Endemann S, Gollapudi R, Valencia R, Stinis CT, Levisay JP, Ernst A, Sawhney NS, Schatz RA, Teirstein PS (2008) Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 29:992–1000PubMedCrossRefGoogle Scholar
  12. 12.
    Patti G, Nusca A, Mangiacapra F, Gatto L, D’Ambrosio A, Di Sciascio G (2008) Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (antiplatelet therapy for reduction of myocardial damage during angioplasty-platelet reactivity predicts outcome) study. J Am Coll Cardiol 52:1128–1133PubMedCrossRefGoogle Scholar
  13. 13.
    Trenk D, Stone GW, Gawaz M, Kastrati A, Angiolillo DJ, Müller U, Richardt G, Jakubowski JA, Neumann FJA (2012) Randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents : results of the TRIGGER-PCI (testing platelet reactivity in patients undergoing elective stent placement on clopidogrel to guide alternative therapy with prasugrel) study. J Am Coll Cardiol 59(24):2159–2164PubMedCrossRefGoogle Scholar
  14. 14.
    Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D, Puri S, Robbins M, Garratt KN, Bertrand OF, Stillabower ME, Aragon JR, Kandzari DE, Stinis CT, Lee MS, Manoukian SV, Cannon CP, Schork NJ, Topol EJ (2011) Standard- vs high dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 305:1097–1105PubMedCrossRefGoogle Scholar
  15. 15.
    Campo G, Parrinello G, Ferraresi P, Lunghi B, Tebaldi M, Miccoli M, Marchesini J, Bernardi F, Ferrari R, Valgimigli M (2011) Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol 57:2474–2483PubMedCrossRefGoogle Scholar
  16. 16.
    Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E, Sabatine MS (2009) Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 360:354–362PubMedCrossRefGoogle Scholar
  17. 17.
    Bauer T, Bouman HJ, van Werkum JW, Ford NF, ten Berg JM, Taubert D (2011) Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. BMJ 343:d4588PubMedCrossRefGoogle Scholar
  18. 18.
    Minarik M, Kopeckova M, Gassman M, Osmancik P, Benesova L (2012) Rapid testing of clopidogrel resistance by genotyping of CYP2C19 and CYP2C9 polymorphisms using denaturing onchip capillary electrophoresis. Electrophoresis 33(8):1306–1310PubMedCrossRefGoogle Scholar
  19. 19.
    Aradi D, Komócsi A, Vorobcsuk A, Rideg O, Tokés-Füzesi M, Magyarlaki T, Horváth IG, Serebruany VL (2010) Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis. Am Heart J 160(3):543–551PubMedCrossRefGoogle Scholar
  20. 20.
    Gaglia MA, Torguson R, Pakala R, Xue Z, Sardi G, Suddath WO, Kent KM, Satler LF, Pichard AD, Waksman R (2011) Correlation between light transmission aggregometry, VerifyNow P2Y12, and VASP-P platelet reactivity assays following percutaneous coronary intervention. J Interv Cardiol 24(6):529–534PubMedCrossRefGoogle Scholar
  21. 21.
    Buch AN, Singh S, Roy P, Javaid A, Smith KA, George CE, Pichard AD, Satler LF, Kent KM, Suddath WO, Waksman R (2007) Measuring aspirin resistance, clopidogrel responsiveness, and postprocedural markers of myonecrosis in patients undergoing percutaneous coronary intervention. Am J Cardiol 99:1518–1522PubMedCrossRefGoogle Scholar
  22. 22.
    Wood S ADAPT-DES: Platelet tests predict stent thrombosis for populations, not individuals. Nov 9, 2011. http://www.theheart.org/article/1306563.doAccessed 15 Jul 2012

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  • Petra Paulu
    • 1
  • Pavel Osmancik
    • 1
  • Petr Tousek
    • 1
  • Marek Minarik
    • 2
  • Lucie Benesova
    • 2
  • Zuzana Motovska
    • 1
  • Frantisek Bednar
    • 1
  • Viktor Kocka
    • 1
  • Petr Widimsky
    • 1
  1. 1.Cardiocenter, 3rd internal-cardiology clinic3rd Medical School, Charles University and University Hospital Kralovske VinohradyPragueCzech Republic
  2. 2.Genomac Research InstitutePragueCzech Republic

Personalised recommendations